Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 4/20 | 0.48 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | CCNK | O75909 | 10/20 | 0.44 |
| ▸ | CDK12 | Q9NYV4 | 10/20 | 0.44 |
| ▸ | CDK2 | P24941 | 10/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 9/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.44 |
| ▸ | CDK9 | P50750 | 9/20 | 0.44 |
| ▸ | IDH2 | P48735 | 1/20 | 0.43 |
| ▸ | CDK7 | P50613 | 2/20 | 0.39 |
| ▸ | CCNH | P51946 | 2/20 | 0.39 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31367812 | 0.99 | IL1B (0.47) | IL1BNLRP3PIM1CCNKCDK12 | |
| SCHEMBL25297096 | 0.80 | IL1B (0.48) | IL1BNLRP3PIM1CCNKCDK12 | |
| SCHEMBL25252231 | 0.80 | IL1B (0.48) | IL1BNLRP3PIM1CCNKCDK12 | |
| SCHEMBL30834046 | 0.80 | IL1B (0.41) | IL1BNLRP3PIM1CCNKCDK12 | |
| SCHEMBL30833876 | 0.80 | IL1B (0.41) | IL1BNLRP3PIM1CCNKCDK12 | |
| SCHEMBL25254743 | 0.79 | IL1B (0.40) | IL1BNLRP3PIM1CDK2CCNT1 | |
| SCHEMBL25303286 | 0.79 | IL1B (0.40) | IL1BNLRP3PIM1CDK2CCNT1 | |
| SCHEMBL23933704 | 0.79 | IL1B (0.38) | IL1BNLRP3 | |
| SCHEMBL23956989 | 0.79 | IL1B (0.38) | IL1BNLRP3 | |
| Hydrochloric Acid SCHEMBL31057109 | 0.79 | IL1B (0.47) | IL1BNLRP3PIM1CCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353830-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4613749-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USE THEREOF | TransThera Sciences (Nanjing), Inc. (CN) | 2025-09-10 | — | — | EP | disclosed |
| US-20240308977-A1 | PYRIDAZINE DERIVATIVES AS INHIBITORS OF NLRP3 | HOFFMANN-LA ROCHE INC. (US) | 2024-09-19 | — | — | US | disclosed |
| CN-118265701-A | Pyridazine derivatives as inhibitors of NLRP3 | 豪夫迈·罗氏有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-117986258-A | NLRP3 inflammation corpuscle inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308977-A1 | PYRIDAZINE DERIVATIVES AS INHIBITORS OF NLRP3 | NLRP3, NLRP1, PYCARD | IL1B 8/4885NLRP3 1/4885PIM1 3555/4885 |
| US-20250353830-A1 | NOVEL COMPOUNDS | UQCRB, CCNB3, C5 | IL1B 2984/4885NLRP3 3745/4885PIM1 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.